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Mutations in the Alpha 1,2-Mannosidase Gene,
MAN1B1, Cause Autosomal-Recessive Intellectual Disability
Muhammad Arshad Rafiq,1,14 Andreas W. Kuss,2,14,15 Lucia Puettmann,2 Abdul Noor,1
Annapoorani Ramiah,3 Ghazanfar Ali,4,5 Hao Hu,2 Nadir Ali Kerio,4 Yong Xiang,3 Masoud Garshasbi,2
Muzammil Ahmad Khan,1,4 Gisele E. Ishak,6 Rosanna Weksberg,7 Reinhard Ullmann,2
Andreas Tzschach,2 Kimia Kahrizi,8 Khalid Mahmood,9 Farooq Naeem,10 Muhammad Ayub,11,12
Kelley W. Moremen,3 John B. Vincent,1,13,* Hans Hilger Ropers,2,14 Muhammad Ansar,3
and Hossein Najmabadi8
We have used genome-wide genotyping to identify an overlapping homozygosity-by-descent locus on chromosome 9q34.3 (MRT15) in
four consanguineous families affected by nonsyndromic autosomal-recessive intellectual disability (NS-ARID) and one in which the
patients show additional clinical features. Four of the families are from Pakistan, and one is from Iran. Using a combination of next-
generation sequencing and Sanger sequencing, we have identified mutations in the gene MAN1B1, encoding a mannosyl oligosaccha-
ride, alpha 1,2-mannosidase. In one Pakistani family, MR43, a homozygous nonsense mutation (RefSeq number NM_016219.3:
c.1418G>A [p.Trp473*]), segregated with intellectual disability and additional dysmorphic features. We also identified the missense
mutation c. 1189G>A (p.Glu397Lys; RefSeq number NM_016219.3), which segregates with NS-ARID in three families who come
from the same village and probably have shared inheritance. In the Iranian family, the missense mutation c.1000C>T (p.Arg334Cys;
RefSeq number NM_016219.3) also segregates with NS-ARID. Both missense mutations are at amino acid residues that are conserved
across the animal kingdom, and they either reduce kcat by ~1300-fold or disrupt stable protein expression in mammalian cells.
MAN1B1 is one of the few NS-ARID genes with an elevated mutation frequency in patients with NS-ARID from different populations.Intellectual disability (ID), also called mental retardation
(MR), is a devastating neurodevelopmental disorder that
has a serious impact on the affected individuals and their
families, as well as on health and social services. It is
believed to occur with a prevalence of ~1%–3% within
the population,1,2 and is frequently the result of genetic
aberrations. ID can present as the sole clinical feature (non-
syndromic [NS]; see MIM 249500), or it can be present
with additional clinical or dysmorphological features (syn-
dromic [S]). Generally speaking, it is much more straight-
forward to identify the genetic cause of S-ID patients
because the comorbid features frequently enable a medical
geneticist to narrow down the suspected cause to a
mutation in a short list of genes, or perhaps in a single
gene. However, for individuals with NS-ID, no secondary
clues assist the molecular diagnosis. ID is significantly
more frequent in males than in females, and it had been
assumed that ~25% of severe cases were X-linked; how-
ever, a recent review suggests that X-linked mutations
contribute to no more than 10% of cases,3 and thus it is
expected that there will be many more autosomal genes1Molecular Neuropsychiatry and Development Lab, Neurogenetics Section, Ce
2Max Planck Institute for Molecular Genetics, Berlin D-14195, Germany; 3Co
30602, USA; 4Department of Biochemistry, Quaid-I-Azam University, Islamab
University, Riyadh 11451, Kingdom of Saudi Arabia; 6Department of Radio
98105, USA; 7Program for Genetic and Genomic Biology, Hospital for Sick C
University of SocialWelfare and Rehabilitation Sciences, Tehran 1985713834, I
Institute of Research & Development, Lahore 54000, Pakistan; 11Tees, Esk, and
UK; 12School for Health andMedicine, University of Durham, Durham TS17 6B
M5T 1R8, Canada
14These authors contributed equally
15Present address: Institute for Human Genetics, Interfaculty Institute for Gene
Greifswald D-17475, Germany
*Correspondence: john_vincent@camh.net
DOI 10.1016/j.ajhg.2011.06.006. 2011 by The American Society of Human
176 The American Journal of Human Genetics 89, 176–182, July 15, 2whose mutations cause NS-ID, both dominant and reces-
sive. However, as a result of the high degree of genetic
heterogeneity, mutations in only seven genes have been
reported to cause NS-ARID, and all of these have been
identified on the basis of mapping regions of autozygosity
or homozygosity-by-descent (HBD) in multiplex consan-
guineous families (reviewed in Kaufman et al.4).
We ascertained three large NS-ARID-affected multiplex
consanguineous families from a farming community in
the Dera Ghazi Khan district, within Punjab province in
Pakistan (MR7, MR8, MR9), one from Sukkur in Sindh
province (MR43), and one from Iran (8600060; Figure 1).
Appropriate informed consent was obtained for all partici-
pants in the study, and institutional research ethics
approval was obtained.
The description of ascertainment, clinical features, and
mapping for families MR7, MR8, and MR9 are given
elsewhere5 but are summarized in Tables 1 and 2. Two
individuals from MR7 (IV:5 and IV:6, age 14 and 13 years,
respectively) were assessed and found to have similar
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Figure 1. Pedigrees of Families MR7, MR8, and MR9 from Dera Ghazi Khan, and from MR43 from Sukkur in Pakistan, and 8600060
from Iran
Filled circles indicate affected individuals. Birth order is not assigned for generation VI in family MR43. Below the pedigrees, electrophe-
rograms from sequence analysis of MAN1B1 are shown, indicating the p.Glu397Lys, p.Trp473*, and p.Arg334Cys mutations, respec-
tively. For the p.Glu397Lys and p.Arg334Cys missense mutations, the panel below the electropherograms shows CLUSTAL 2.1 multiple
sequence alignment indicating conservation of the substituted amino acids in MAN1B1 orthologs across the animal kingdom in red.
Nonconserved residues are shown with yellow highlighting. Photographs of the affected individuals are available on request from
the corresponding author (signing of a confidentiality and nondisclosure agreement is required).milestones and began walking at age 4 yr. Speech was also
delayed, but they are now both able to speak in sentences,
albeit limited to immediate and day-to-day needs. They
are toilet trained but require assistance with bathing and
dressing. Both have hyperphagia and are overweight. MR7Table 1. Summary of Clinical Information
Family ID
Mutation (Nucleotide;
Protein) Gender Age IQ
MR7- IV:5 c.1189G>A; p.Glu397Lys M 14 45–55
MR7- IV:6 c.1189G>A; p.Glu397Lys F 13 45–55
MR8- IV:2 c.1189G>A; p.Glu397Lys M 10 50–60
MR8- IV:1 b c.1189G>A; p.Glu397Lys F N.K.
MR9-II-3 c.1189G>A; p.Glu397Lys F 9 45–55
MR9-II-1 c.1189G>A; p.Glu397Lys M 18 45–55
MR43-VI:4 c.1418G>A; p.Trp473* M 9 55–65
MR43-VI:1 c.1418G>A; p.Trp473* F 16 55–65
MR43-VI:5 c.1418G>A; p.Trp473* M 8 55–65
8600060-V:1 c.1000C>T; p.Arg334Cys M 11 59
8600060-V:2 c.1000C>T; p.Arg334Cys F 25 63
8600060-V:3 c.1000C>T; p.Arg334Cys F 23 56
Nucleotide sequence uses NM_016219.3, the reference mRNA sequence for MAN
a NK: not known or not measured.
b Now deceased (from hepatitis C).
The AmIV:5 also suffers from asthma. Brain MRI scan for MR7-
IV:5 was examined by a radiologist (GI), and showed no
evidence of white-matter abnormality within the cere-
bellum or cerebrum; however, we observed a small promi-
nent perivascular space in the right parietal lobe, as well asSyndromic/
Nonsyndromic
OFC
(cm)
Height
(cm)
Obesity
(Weight in Kg) Epilepsy
NS 55.5 155 þ (68) -
NS 54.5 150 þ (60) -
NS NKa NKa - -
NS NKa NKa - -
NS 51 119 - (23) -
NS NKa NKa - þ
S 53 130 - (26.9) þ
NKa 55 138 - (36) -
S 53 121 - (19) -
NS 53 136 - -
NS 55 155 - -
NS 53.5 154 - -
1B1.
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Table 2. Details of Examination of Photographs of Affected Family Members
Family ID
Mutation (Nucleotide;
Protein)
Physical Features and Dysmorphology
Eyes Head and Ears Face Hands Feet
MR7- IV:5 c.1189G>A; p.Glu397Lys down-slanting palpebral
fissures; thin, sparse
eyebrows
mild dolicocephaly;
short neck
broad nose
MR7- IV:6 c.1189G>A; p.Glu397Lys down-slanting palpebral
fissures; thin, sparse
eyebrows
mild dolicocephaly;
short neck
broad nose
MR8- IV:2 c.1189G>A; p.Glu397Lys NKa NKa NKa NKa NKa
MR8- IV:1b c.1189G>A; p.Glu397Lys NKa NKa NKa NKa NKa
MR9-II:3 c.1189G>A; p.Glu397Lys Arched, sparse eyebrows; triangular,
pointed chin
MR9-II:1 c.1189G>A; p.Glu397Lys Arched, sparse eyebrows;
long eyelashes
triangular, pointed
chin flat philtrum
NKa NKa
MR43-VI:4 c.1418G>A; p.Trp473* down-slanting palpebral
fissures; hyperteloric
flat occipitus;
low-set ears
long face; flattened
malar regions; short
philtrum; everted lips;
broad nasal root;
small chin
fifth-finger
clinodactyly
partial second-
and third-toe
syndactyly
MR43-VI:1 c.1418G>A; p.Trp473* NKa NKa NKa NKa NKa
MR43-VI:5 c.1418G>A; p.Trp473* down-slanting palpebral
fissures; hyperteloric
NKa long face; flattened
malar regions; short
philtrum; broad
nasal root; small chin
NKa NKa
8600060-V:1 c.1000C>T; p.Arg334Cys down-slanting palpebral
fissures; hyperteloric;
broad, long eyebrows
flat philtrum; thin
upper lip; triangular,
pointed chin;
prominent nose
8600060-V:2 c.1000C>T; p.Arg334Cys down-slanting palpebral
fissures; hyperteloric;
broad, long eyebrows
mild dolicocephaly flat philtrum; thin
upper lip; triangular,
pointed chin;
prominent nose
8600060-V:3 c.1000C>T; p.Arg334Cys down-slanting palpebral
fissures; hyperteloric;
broad, long eyebrows
mild dolicocephaly flat philtrum; thin
upper lip; triangular,
pointed chin;
prominent nose
Nucleotide sequence uses the reference mRNA sequence for MAN1B1, NM_016219.3. Photographs will be made available to researchers by the corresponding
author, upon signing a nondisclosure agreement.
a NK: not known (photographs or clinical information is unavailable to researchers).
b Now deceased (from hepatitis C).cerebellar and cerebral sulci that are mildly prominent but
not enough so to constitute volume loss or atrophy, espe-
cially given that the ventricles are normal in size (see Fig-
ure S1).MR8-IV:1 died in 2009 (fromhepatitis C).MR8-IV:2
(age 10 years) has a slightly higher level of functioning
thanMR7-IV:5 and IV:6 and speaks in sentences. He is toilet
trained can dress himself if supervised. He attends school,
can read words of one or two syllables, and can count to
ten. MR9-II:1 (age 18 years) has a developmental trajectory
similar to that of MR7-IV:5 and IV:6. He is able to speak in
sentences but is unable to read or write. Inappropriate
sexualized behavior is a major cause for concern to the
family. He has epileptic seizures, which started at 10 years
of age. He has at least one episode per week. Episodes begin
with twitching of the facial muscles, then become general-
ized, at which point he loses consciousness. The seizures
have a tonic and then clonic phase and last for several178 The American Journal of Human Genetics 89, 176–182, July 15, 2minutes, after which he takes 3 to 4 hr to recover. During
this period he is drowsy and disorientated. He frequently
becomes incontinent during the fit. Sometimes the family
members are able to avert a fit by distracting his attention.
MR9-II:3 (age 9 years) has a developmental trajectory
similar to that of her sibling, MR9-II:1, but no epilepsy re-
ported to date. Electroencephalographs were not available
for MR9-II:1. Verbal and physical aggression is a common
feature among affected individuals from MR7 and MR9,
but not for individual MR8-IV:2. Mild dysmorphic features
were noted for members of families MR7, MR8, and MR9
(see Table 2); however, these cannot be excluded as familial
traits, and the families are categorized as nonsyndromic.
It was established that MR7, MR8, and MR9 all shared
a HBD region on chromosome 9 (9q34.3; between SNPs
rs11103117 and rs12238423 [nucleotides 137,667,734–
139,811,104 (UCSC March 2006)]; Figure 2), and the locus011
Figure 2. Ideogrammatic Representation Indicating the Overlapping HBD Regions for All Three Families on 9q34.3, the RefSeq
Genes within the Common Region, the Genomic Organization ofMAN1B1, and the Location within the Gene for the Three mutationswas assigned as MRT15.5 The critical region was 2.14 Mb,
and linkage analysis gave LOD score ¼ 4.8.5 Although
we were unable to establish familial connections in the
ancestry of families MR7, MR8, and MR9, comparison of
haplotypes suggests a common founder.
MR43 has three affected members, VI:1, VI:4, and VI:5
(ages 16, 9, and 8, respectively) with milder, higher func-
tioning intellectual disability. On assessment, VI:4 showed
delayed developmental milestones; he sat at 9 months
and walked at 2 years. He can talk in sentences and is
independent in terms of self care. He can help with chores
around the farm. He is sociable and caring but can become
verbally and physically aggressive upon provocation and
can damage property. On the basis of the assessment, he
has mild ID (estimated IQ 55–65). He has epileptic
seizures, which started at 6 years of age. These are primary
generalized seizures, which start with eye rolling followed
by loss of consciousness. Electroencephalographs were
not available. His physical appearance shows facial dys-
morphic features, including down-slanting palpebral fis-
sures, hypertelorism, a long face, flattened malar regions,
a short philtrum, everted lips, a broad nasal root, and
a small chin (Table 2). He has fifth-finger clinodactyly.
His elder sister (IV:1) and younger brother (IV:5) have a
similar developmental trajectory and level of functioning
and similar dysmorphic features (IV:1 was not assessed),
but no history of epilepsy. Brain computed tomography
(CT) scan for an VI:4 was examined by a radiologist (GI)
and showed no apparent abnormalities, including noThe Amobvious white-matter abnormalities or obvious cerebellar
atrophy.
For MR43, an HBD region overlapped with that of
MRT15 (9q34.3-qter: SNPs rs11103399– rs11137379;
nucleotides 136,609,628–140,147,760; Figure 2).
The Iranian family, 8600060, had three affected
members of ages 11, 23, and 25 years. They had mild to
moderate NS-ARID, which was ascertained and mapped
as previously described6 to 9q34.3 (SNPs rs2031825–
rs11137163, 137,166,820–139,653,199; Figure 2), and
linkage analysis gave an LOD score ¼ 3.1.6 On assessment,
the 11-year-old boy (V:1) showed only slight develop-
mental delay. He started to walk at 1.5 years of age. His
speech started at age 2.5. He speaks well and can count
and use money. He can dress and wash independently
and perform day-to-day tasks such as answering the tele-
phone. He has no history of epilepsy, and just mild ID.
His sister, V:3, a 23-year-old, has slight developmental
delay, but it is more severe than that of her brother, and
she shows aggressive behavior. She can dress and wash
independently but cannot count or use money. Her speech
is less advanced than her brother’s. She has no history of
epilepsy. Her older sister, V:2, age 25 years, was more
delayed than her younger siblings. She began walking at
4 years. She speaks in sentences but cannot count or use
money. She has problems with overeating and aggression
and has a history of generalized epilepsy. Study of photo-
graphs of affected individuals from this family suggested
common facial features, including a flat philtrum anderican Journal of Human Genetics 89, 176–182, July 15, 2011 179
Figure 3. Paralogues of MAN1B1 in Humans
Are Also Type 1 Mannosidases and Contain
Glycosyl Hydrolase Family 47 Domains
Arg334 and Glu397 are both conserved across
these paralagous sequences. Alignments were
performed with CLUSTAL 2.1 multiple sequence
alignment.prominent nose. However, because photographs of other
family members were not available, these cannot be
excluded as familial traits, and the family is categorized
as nonsyndromic (see Tables 1 and 2).
When all the Pakistani and Iranian families are taken
into consideration, a combined critical region spanning
nucleotides 137,667,734–139,653,199 (~2.0Mb) was likely
to harbor a gene in which mutations lead to NS-ARID (see
Figure 2). This critical region contains 82 RefSeq coding
genes (UCSC hg18 March 2006).
For the Iranian family, we performed next-generation
sequencing by enrichment of the exonic regions within
the linkage interval by using a custom Agilent SureSelect
array, followed by sequencing with the Illumina Genome
Analyzer II platform. Analysis of prospective changes from
the critical region indicated DNA variants in just three
genes: GPSM1 [MIM 609491] (one base pair deleted at
Chr9:139,235,486 (hg19); RefSeq number NM_015597.4;
c.1243 delA [p. Thr415Glnfs*55]), SOHLH1 [MIM 610224]
(missense change: c. 916C>A [p.Leu306Met]; RefSeq
number NM_001101677.1) and MAN1B1 [MIM 604346]
(missense change: c.1000C>T [p.Arg334Cys]; RefSeq
numberNM_016219.3).However, only theMAN1B1 change
segregated in pedigree 8600060. This change, which occurs
in exon 7, was not present in 155 Iranians or 191 Germans.
For the Pakistani families, a number of genes were
selected as candidates for sequencing, but sequence anal-
ysis excluded INPP5E [MIM 613037], GRIN1 [MIM
138249], ABCA2 [MIM 600047], CACN1AB, EHTM1,
KCNT1 [MIM 608167], CAMSAP1, OLFM1 [MIM 605336],
GLT6D1 [MIM 613699], SEC16A [MIM 612854], LHX3
[MIM 600577], ANAPC2 [MIM 606946], PNPLA7 [MIM
612122), and TUBB2C [MIM 602660]. Sequence analysis
of GPSM1, SOHLH1, and MAN1B1 was then undertaken.
The same 1 bp deletion was observed in GPSM1 in an
affected member of MR43, however this did not segregate,
and it was present in homozygous form in an unaffected
sibling. This deletion occurs within the last exon of
GPSM1, but the location is only present within the coding
region for one of the four known isoforms of the gene
(RefSeq; UCSC Hg18, March 2006) and is either within
intron 9 or upstream for the other isoforms. No changes
were found in SOHLH1, but a missense mutation in exon
8 and a nonsense mutation in exon 9 were found in
MAN1B1 for MR7, MR8, MR9 (NM_016219.3: c. 1189G>A
[p.Glu397Lys]), and MR43 (NM_016219.3: c.1418G>A
[p.Trp473*]), respectively.
Both the Arg334 and Glu397 residues are conserved
across evolution of the animal kingdom (Figure 1). Further-
more, these residues are also conserved across paralogous180 The American Journal of Human Genetics 89, 176–182, July 15, 2sequences that are known to have similar enzymatic func-
tions but in different cellular contexts (Figure 3). The
c.1189G>A substitution creates a StyI restriction endonu-
clease cutting site, and the c.1418G>A destroys a BamHI
restriction site. We used PCR followed by either StyI or
BamH1 digestion to screen a cohort of 252 Pakistani
controls, but the mutant alleles were not detected. None
of the three MAN1B1 substitutions have been reported in
any SNP databases to date and were not present in the
1000 Genomes Version 60.37e.
MAN1B1 encodes the protein endoplasmic reticulum
mannosyl-oligosaccharide1,2-alpha-mannosidase (ERManI;
EC¼ 3.2.1.113). ERManI and other class 1 a-mannosidases
are members of the glycosyl hydrolase family 47 (GH47),
are believed to be key enzymes involved in the maturation
of N-glycans in the secretory pathway,7,8 and contribute
to the timing and disposal of misfolded glycoproteins
through the endoplasmic-reticulum-associated degrada-
tion pathway.9 Enzyme activity involves a direct Ca2þ-
mediated interaction between the enzyme and substrate,8
and the protein forms an (aa)7 barrel structure with the
Ca2þ ion bound at the core of an active-site pocket in the
center of the barrel.9 The Arg334 residue, which is mutated
in the Iranian family, is believed to be located at the base of
the active-site pocket.9 The Glu397 residue, which is
mutated in the Pakistani MR7,MR8, and MR9 families, is
also located at this active-site pocket, where it interacts
with glycan substrates (see Figure 4; also see Movie S1).9
Arg334 interacts via hydrogen bonding with the 40 OH
on the glycone in the 1 subsite, and the Glu397 residue
is involved in hydrogen bonding to the 60 OH of the þ1
mannose residue. Each of these interactions probably
makes a minor energetic contribution relative to others in
the active site,10 but the p.Arg334Cysmutationmight alter
the electrostatics in the active site inways that are not easily
predicted. The p.Glu397Lysmutation is likely to be disrupt-
ing, partially because of the loss of hydrogenbonding to the
side chain but also because the longer Lys side chain would
probably provide steric hindrance to docking of the þ1
residue. Thus, both missense mutations would probably
interfere indirectly with the enzyme’s ability to bind and
recognize the appropriate oligosaccharide substrate. The
cDNA encoding the MAN1B1 catalytic domain was used
for site-directed mutagenesis, as described previously.9
The constructs were used for transient transfection of
HEK293 cells. The wild-type (wt) construct was secreted
well and was purified on a Ni2þ-NTA column; however,
the Cys334 construct was expressed and secreted at ~20%
of that of wt levels, and Lys397 was expressed and secreted
at <5% of wt levels. Although the amount of expressed011
Table 3. Kinetic Analysis of the MAN1B1 Cys334 Mutation
Enzyme
Form kcat (s
1) Km (mM)
kcat/Km
(s1/M)
kcat/Km
kcat/Km(wt)
Wild -type 1.31 5 0.24 1335 4 9850 1
Cys334 0.000987 5 0.000015 20.6 5 1.3 47.9 0.00486
The coding region for the catalytic domain of MAN1B19 was subcloned into
a modified version of the pXLG vector15 encoding an NH2-terminal signal
sequence from the T. cruzi lysosomal mannosidase,16 83 His tag, Strep II
tag, and then a TEV protease cleavage site and the MAN1B1 coding region.
The construct was transiently transfected into HEK293 suspension culture cells
(Freestyle 293-F, Invitrogen) via the TransIT Pro transfection reagent (Mirus).
Five days after transfection the conditioned medium was harvested, and the
recombinant enzyme was purified by Ni2þ-NTA chromatography (QIAGEN)
and concentrated by ultrafiltration. Enzyme assays were performed with
Man9GlcNAc2-PA as a substrate.
9,10 Substrate concentrations varying from
5 mM to 1 mM. Enzymatic cleavage was monitored by HPLC, and kinetic values
were determined with SigmaPlot.
Figure 4. 3D Protein Structure for MAN1B1 Indicating the Loca-
tion of Missense Residues
The structure shows a transparent surface representation of the
enzyme in gray and a stick representation of the glycan substrate
(thiodisaccharide) in yellow; the mannose residues in the 1
and þ1 subsites are indicated. The Ca2þ ion interacting with the
20 OH and 30 OH of the glycone residue in the 1 subsite is indi-
cated with orange spacefill. The two amino acids that are mutated,
Arg334 andGlu397, are shown in stick form in blue and are clearly
located close together; they are believed to form hydrogen bonds
with the substrate. Themolecular display was generated withMac-
Pymol 1.3 and the PDB file 1X9D.9 See Movie S1 for a video of the
molecular structure.protein for the Lys397 mutant was too low for enzyme
activity to be measured, kinetic analysis of the Cys334
mutant indicated a 1327-fold reduction in kcat, a 6.4-fold
reduction inKm,anda205-folddecrease inKcat/Km(Table3).
It is highly probable that these missense mutations
destabilize the protein and thus negatively affect folding
and secretion.
The Trp473 nonsense mutation identified in family
MR43 is thus likely to result in a truncated form of the
protein missing many of the residues required for substrate
recognition, as well as the Ca2þ-binding Thr688 residue.
Furthermore, it occurs in exon 9 of a 13 exon gene and
therefore most likely leads to nonsense-mediated RNA
decay so that only a little mRNA, if any, would survive to
protein translation. However, mRNA was not available
from any MR43 family members, and as such, we were
unable to confirm this experimentally.
The lysosomal-storage disease mannosidosis (MIM
248500 for amannosidosis; MIM 245100 for bmannosido-
sis) is an autosomal-recessive condition caused by muta-
tions within genes for lysosomal a-mannosidase enzyme
MAN2B1 (MIM 609458) and lysosomal b-mannosidase
enzyme MANBA (MIM 609489). Alpha-mannosidosis is
a rare condition, with an estimated prevalence between
1:500,000 and 1:750,000,11,12 and it varies in severity
from prenatal lethal forms to late-onset forms with slow
progression. The main features are intellectual disability,The Amhearing loss, myopathy, skeletal abnormalities, and facial
dysmorphic features, as well as vulnerability to infections
(see GeneReviews in Web Resources). Brain magnetic reso-
nance imaging (MRI) of a-mannosidosis patients typically
show white-matter abnormalities as well as cerebellar
atrophy and other structural anomalies (see GeneReviews
in Web Resources). b -mannosidosis is even rarer, and
clinical features include intellectual disability, behavioral
abnormalities, and hearing loss; occasionally, there is also
facial dysmorphism, skeletal deformation, susceptibility
to respiratory infections, and skin lesions.14 The clinical
features of the four families identified with MAN1B1
missense mutations indicate nonsyndromic ARID because
only mild dysmorphic features that could not be excluded
as family traits were observed, whereas clear dysmorphic
features were noted for the family with the nonsensemuta-
tion (MR43; see Table 2; photos of patients fromMR7 (IV:5,
IV:6), MR8 (IV:2), MR9 (II:1, II:3), andMR43 (VI:4, VI:5), as
well as individuals V-1, V:2, and V:3 from family 8600060,
were examined by R.W.). A more detailed physical exami-
nation might be required in order to reveal more subtle
anomalies.
Thus, we believe that mutation of this endoplasmic
reticulum mannosidase gene results in NS-ARID rather
than mannosidosis, and thus the disease mechanism is
different from disease-causing mutations in the lysosomal
a and b mannosidase genes MAN2B1 and MANBA. The
identification of mutations causing NS-ARID in MAN1B1
suggests that the ER-associated degradation (ERAD) path-
way is a new disease-associated pathway, and this leads
us to further speculate that disruption of other ERAD
pathway molecules might result in similar clinical presen-
tation.
Thus, mutations in MAN1B1 have been found to cause
NS-ARID. Furthermore, this is one of the rare cases of NS-
ARID genes with increased mutation frequency, and it is
tempting to speculate that future investigations into the
molecular causes of NS-ARID in larger numbers of patients
might demonstrate that disruption of MAN1B1 accounts
for more than one percent of the patients.erican Journal of Human Genetics 89, 176–182, July 15, 2011 181
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